Search

Pacific Biosciences of California Inc

Atvērts

SektorsVeselības aprūpe

1.34 -0.74

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.33

Max

1.3900000000000001

Galvenie mērījumi

By Trading Economics

Ienākumi

-45M

-53M

Pārdošana

1.8M

39M

EPS

-0.14

Peļņas marža

-135.914

Darbinieki

485

EBITDA

-32M

-38M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+41.79% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 4. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-21M

420M

Iepriekšējā atvēršanas cena

2.08

Iepriekšējā slēgšanas cena

1.34

Ziņu noskaņojums

By Acuity

67%

33%

293 / 339 Rangs Healthcare

Pacific Biosciences of California Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. sept. 23:11 UTC

Pacific Biosciences of California is gaining in after-market trading, supported by a positive performance backdrop and four consecutive higher closes.

2026. g. 14. sept. 20:05 UTC

Correlated Moves

Pacific Biosciences of California is higher today, influenced by social media discussions on Tempus AI's $80 price target and broader market sentiment.

2026. g. 11. sept. 19:02 UTC

Pacific Biosciences of California is trading higher, continuing its recovery after three sessions of declines. No specific news was identified for the upward movement.

2026. g. 9. sept. 20:01 UTC

News

Pacific Biosciences of California shares are lower after UBS initiated coverage with a Neutral rating and a price target of $1.35.

2026. g. 8. sept. 23:56 UTC

Pacific Biosciences of California Inc. shares are higher in after-market trading, despite fluctuations, and remain above their 20-day moving average.

2026. g. 3. sept. 19:56 UTC

Pacific Biosciences of California is lower today with no specific news. The broader market sees falling Treasury yields amid jobless claims data.

2026. g. 2. sept. 23:46 UTC

Pacific Biosciences of California is higher in after-market trading, despite no specific news, amid a weaker ADP payrolls report that may ease rate hike concerns.

2026. g. 1. sept. 23:46 UTC

Pacific Biosciences of California remained roughly flat during after-market hours. This follows five consecutive sessions of lower finishes.

2026. g. 31. aug. 20:07 UTC

Pacific Biosciences is trading lower, reflecting broader market declines amid heightened interest rate hike expectations from the Jackson Hole Economic Symposium.

2026. g. 28. aug. 23:36 UTC

Pacific Biosciences is trading higher in after-market hours, reaching a level significantly above Friday's close amid broader market pressures from rising Treasury yields.

2026. g. 27. aug. 20:07 UTC

Pacific Biosciences of California is lower today, with no specific news driving the decline. The broader market has also been down since Wednesday.

2026. g. 26. aug. 23:06 UTC

Pacific Biosciences of California traded roughly flat in after-market hours, with no specific news driving the activity. The stock remains near its one-month range's upper end.

2026. g. 25. aug. 23:01 UTC

Pacific Biosciences is lower in after-market trading, with no specific news identified. The broader market has also retreated amid falling crude oil prices.

2026. g. 24. aug. 23:01 UTC

Pacific Biosciences of California is trading higher in after-hours, recovering from an initial low and remaining above its 20-day moving average.

2026. g. 21. aug. 22:51 UTC

Correlated Moves

Shares of Pacific Biosciences of California declined in after-market trading, continuing a downward trend amid broader market weakness and rising Treasury yields.

2026. g. 20. aug. 19:51 UTC

Correlated Moves

Pacific Biosciences is lower today, reflecting broader market declines and trading near the lower end of its one-month range.

2026. g. 19. aug. 23:11 UTC

Correlated Moves

Pacific Biosciences of California shows a modest increase in after-market trading, reflecting stability amid a broader positive trend in correlated assets.

2026. g. 18. aug. 23:16 UTC

Correlated Moves

Pacific Biosciences shares declined in after-hours trading, continuing a downward trend since Tuesday's close, amid broader market sentiment reflected by the Russell 2000 Index.

2026. g. 17. aug. 19:11 UTC

News

Pacific Biosciences reported second-quarter revenue of $39 million, with shares trading higher today after initially dropping. The company is undergoing a leadership transition.

2026. g. 14. aug. 19:36 UTC

Correlated Moves
News

Pacific Biosciences reported second-quarter revenue of $39.01 million, missing estimates. Shares are trading lower amid concerns over funding constraints and adoption challenges.

2026. g. 13. aug. 23:06 UTC

Correlated Moves

Pacific Biosciences of California Inc. gained modestly in after-market trading, reflecting broader market trends seen in correlated assets.

2026. g. 12. aug. 23:41 UTC

Pacific Biosciences shares are lower in after-market hours, trading below their 20-day moving average amid easing inflation concerns and broader market conditions.

2026. g. 11. aug. 20:06 UTC

Pacific Biosciences of California is trading higher in a routine session. The stock remains below its 20-day moving average despite today's gains.

2026. g. 10. aug. 23:21 UTC

Pacific Biosciences of California Inc. shares are higher in after-market trading, recovering from earlier losses and gaining since Monday's close.

2026. g. 7. aug. 22:56 UTC

Correlated Moves

Pacific Biosciences shares are lower in after-market trading, retracing from an initial gain as 10X Genomics declines, impacting market sentiment.

2026. g. 6. aug. 23:11 UTC

Pacific Biosciences of California is higher in after-market trading, reflecting positive momentum since Thursday's close, despite being below its 20-day moving average.

2026. g. 5. aug. 23:01 UTC

News

Pacific Biosciences reported lower second-quarter revenue and a wider EPS loss, prompting a reduction in full-year sales guidance. Shares are down in after-market trading.

2026. g. 4. aug. 21:36 UTC

Pacific Biosciences of California remained roughly flat after market hours. Broader market gains were driven by a decline in crude oil prices.

2026. g. 3. aug. 23:36 UTC

Pacific Biosciences of California Inc. shares are roughly flat after-market, remaining near the lower end of their one-month trading range.

2026. g. 31. jūl. 19:46 UTC

News
Correlated Moves

Pacific Biosciences of California is trading lower amid a report citing annual sales declines and cash burn concerns impacting its growth outlook.

Salīdzinājums

Cenas izmaiņa

Pacific Biosciences of California Inc Prognoze

Cenas mērķis

By TipRanks

41.79% augšup

Prognoze 12 mēnešiem

Vidējais 1.9 USD  41.79%

Augstākais 3 USD

Zemākais 1.25 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pacific Biosciences of California Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

5 ratings

2

Pirkt

2

Turēt

1

Pārdot

Noskaņojums

By Acuity

293 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat